Edogawa-ku, Japan

Akihiro Imura


Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 15(Granted Patents)


Location History:

  • Edogawa-ku, JP (2005 - 2008)
  • Tokyo, JP (2007 - 2010)

Company Filing History:


Years Active: 2005-2010

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Akihiro Imura: Innovator in Antitumor Compounds

Introduction

Akihiro Imura is a prominent inventor based in Edogawa-ku, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumor compounds. With a total of 7 patents to his name, Imura's work has the potential to impact cancer treatment significantly.

Latest Patents

One of Imura's latest patents is a method for producing pentacyclic taxans. This innovative process allows for the efficient and inexpensive production of taxan derivatives, which are useful as oral-administrable antitumor compounds. The method involves processing a compound of formula (1) with an alkali metal permanganate to produce a compound of formula (2). This compound may serve as a starting material for developing oral-administrable antitumor compounds.

Career Highlights

Imura has dedicated his career to advancing pharmaceutical research and development. His work at Daiichi Pharmaceutical Co., Ltd. has positioned him as a key player in the industry. His innovative approaches to drug formulation and production have garnered attention and respect from his peers.

Collaborations

Throughout his career, Imura has collaborated with notable colleagues, including Yoshihiro Takayanagi and Kouji Sato. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Akihiro Imura's contributions to the field of pharmaceuticals, particularly in developing antitumor compounds, highlight his role as an influential inventor. His innovative methods and collaborative spirit continue to drive advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…